| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
doi: 10.3322/caac.21660
|
| [2] |
Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapⅡ)[J]. Am J Cancer Res, 2015, 5(9): 2892-2911.
|
| [3] |
Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acqui-red resistance to first- and second-generation EGFR tyrosine kinase inhibitors[J]. Ann Oncol, 2018, 29(Suppl-1): i10-i19. DOI: 10.1093/annonc/mdx703.
doi: 10.1093/annonc/mdx703
|
| [4] |
Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study[J]. J Clin Oncol, 2020, 38(2): 115-123. DOI: 10.1200/JCO.19.01488.
doi: 10.1200/JCO.19.01488
pmid: 31682542
|
| [5] |
Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer(NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. Lancet Oncol, 2019, 20(5): 625-635. DOI: 10.1016/S1470-2045(19)30035-X.
doi: 10.1016/S1470-2045(19)30035-X
|
| [6] |
Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401. DOI: 10.1016/S2213-2600(19)30084-0.
doi: 10.1016/S2213-2600(19)30084-0
|
| [7] |
周丽亚, 李小利, 曹子肖, 等. 白蛋白结合型紫杉醇与培美曲塞分别联合顺铂治疗驱动基因阴性晚期肺腺癌的临床观察[J]. 国际肿瘤学杂志, 2021, 48(10): 596-601. DOI: 10.3760/cma.j.cn371439-20210210-00117.
doi: 10.3760/cma.j.cn371439-20210210-00117
|
| [8] |
Zhang Y, Sheng J, Yang Y, et al. Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis[J]. Oncotarget, 2016, 7(15): 20093-20108. DOI: 10.18632/oncotarget.7713.
doi: 10.18632/oncotarget.7713
|
| [9] |
Chen Y, Wen S, Wu Y, et al. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2021, 163: 103393. DOI: 10.1016/j.critrevonc.2021.103393.
doi: 10.1016/j.critrevonc.2021.103393
|
| [10] |
Lam TC, Tsang KC, Choi HC, et al. combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure[J]. Lung Cancer, 2021, 159: 18-26. DOI: 10.1016/j.lungcan.2021.07.004.
doi: 10.1016/j.lungcan.2021.07.004
pmid: 34303276
|
